Skip to main content

Table 2 Comparison of serum concentrations of bone biomarkers between healthy controls and RA patients and changes of those over 6 months in the RA patients

From: Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan

  HC RA
Baseline p-value
vs. HCa
3 months p-value
vs. baselineb
6 months p-value
vs. baselineb
Dkk-1, pg/ml 4362 (2866–5026) 3340 (2573–4243) 0.25 3260 (2519–4282) 0.86 3242 (2689–4251) 0.98
SOST, pg/ml 2509 (1939–3315) 2616 (1983–3279) 0.64 2588 (2171–3506) 0.68 2738 (2127–3465) 0.62
OC, pg/ml 28,492(18700–35,923) 17,109 (11075–35,817) 0.099 18,271 (12754–31,724) 0.52 21,533 (14559–28,715) 0.26
OPG, pg/ml 1036 (896–1184) 951 (768–1387) 0.76 1082 (903–1469) 0.085 1181 (903–1469) 0.016
OPN, pg/ml 9053 (6282–14,337) 22,928 (17305–37,566) < 0.0001 23,689 (13849–32,156) 0.76 21,818 (13895–33,550) 0.85
  1. The data are median (interquartile range, Q1–4–Q3/4) or number (percentage)
  2. aComparisons of the serum concentration of bone biomarkers between HC and RA were analyzed using the Mann-Whitney U-test
  3. b The changes in the serum concentration of bone biomarkers from baseline were analyzed using the Wilcoxon signed ranks test. HC Healthy control, PD Power Doppler, RA Rheumatoid arthritis